Compare Ascendis Pharma A/S (ASND) vs Gitlab Inc (GTLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Gitlab Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Gitlab Inc trades at $32.87 (market cap $5.48B). The key difference: Ascendis Pharma A/S is far larger — about 3.2× Gitlab Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| ASND | GTLB | |
|---|---|---|
Market Cap | $17.74B | $5.48B |
Sector | Health | Technology |
52-Week High | $277.18 | $51.04 |
52-Week Low | $163.32 | $19.42 |
Enterprise Value | $18.11B | $4.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
GitLab (GTLB) trades at $32.42, down 4.25% today, but maintains a bullish technical outlook with strong moving average signals. The company shows impressive revenue growth, reaching $759 million in 2025, with consistent earnings beats in recent quarters. Analyst sentiment is mixed with 36.7% buy ratings, while the stock trades near consensus price target of $31.93. Recent news highlights GitLab's leadership in DevSecOps and strategic AI partnerships.
GitLab presents a growth story with strong market positioning but faces profitability challenges. The stock offers upside potential from AI-driven software demand and enterprise adoption, though high valuation multiples and negative cash flow pose risks. Investors should weigh the company's strategic position against its path to sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
